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2007 she was operated of a left upper lobectomy and lymphadenectomy. The pathology report consistent with metastatic ade-
nocarcinoma of endometrial origin of 4 cm in maximum diameter that do not invades the visceral pleura. The tumor near the
surgical resection margin invades and occludes the bronchial lumen completely. The prevascular lymphadenopathy was free
of tumor involvement. With the diagnosis of lung metastasis of an endometrial adenocarcinoma the patient was sent to our
service for local consolidation therapy. Treatment plan, we administered 30Gy in 6 fractions to the bronchial stump, 5Gy each
session, from 27 September to October 31 of 2007. In each session were performed a bronchoscopy and a dosimetric planning
CT. Tolerance to treatment was excellent. Last control CT was in 3/2012 and informed of a complete response.
Conclusion. After ﬁve year the patient remains disease free. Endobronchial brachytherapy is an effective alternative to achieve
local control after surgery of metastasis.
http://dx.doi.org/10.1016/j.rpor.2013.03.038
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Objective. Review the results of toxicity in patients (p) with prostate cancer treated with permanent brachytherapy with seeds of
I125.
Material and methods. Criteria of incorporation: p with low risk prostate cancer dose 145Gy; intermediate risk, combined Exter-
nal Radiotherapy 45Gy and 110Gy; all had prostate volume <45 cm3 and IPSS minor than 12. The planning system was real
time intraoperatory system SPOT, and SEED-Selectron (Nucletron®). We followed ESTRO guidelines and dose was registered in
neurovascular bundles by D90. IPSS and toxicity has been recorded according to the scale CTC v.4 at diagnosis and the reviews.
Results. 121 patients included (p) in the period of Dic 2008 to Dec 2012. The treatment was exclusive in 95 p (77%) of low risk,
combined in 26p (23%) of intermediate risk. Characteristics: T1c: 99p (82%), T2a 17p (11%), T2c 5p (7%); Gleason 4–5: 2p (2%), 6:
95p (79%), 7: 24p (19%). Medium dose: D90 PTV: 162.2Gy (142.4–188.2); boost: 120.34 (110.3–129.5); D30 urethra md: 112%; D10
urethra med: 119%; D2cc rectum: 89.5%. With median of follow-up: 14.8m, biochemical and local failure (conﬁrmed PET-colina):
1p (0.8%). The toxicity to 12m includes: in the Table 1. G1 G2 G3 Frequency 1 (1.8%) 16 (13.2%) – Nicturia 25 (20.7%) 2 (1.7%) 1 (0.8%)
Incontinency 0 Proctitis 0 1 (0.8%) Impotence 6 (5%) 12 (9.9%). It has not been correlation between the toxicity urinary GII and
D10 uretral, neither impotence GII and D90 in neurovascular bundles: D90 No impotence: 93.8Gy vs D90 G1–2: 98.1Gy (p: ns).
Conclusion. Intraoperatory real time planning reduces late urinary and sexual toxicity. We did not ﬁnd correlation between the
urinary toxicity GII and D10 uretral, neither impotence GII and D90 in neurovascular bundle, although a major follow-up is
necessary.
http://dx.doi.org/10.1016/j.rpor.2013.03.039
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Introduction. Brachytherapy with 125-I seeds in low-intermediate risk prostate carcinoma is a very save treatment, if we respect
the constraint over rectum and urethra as ESTRO recommend Objective Analysis dose to rectum and urethra at our institution
on incorporation of brachytherapy with permanent implants of 125-I seeds in prostate carcinoma with real-time planiﬁcation
and Quick-Link system.
Methods. Between March of 2011 and December of 2012 were performed 41 prostate brachytherapy applications with permanent
implants of 125-I seeds in patients with prostate Adenocarcinoma low-intermediate risk, as monotherapy or combined with
EBRT. Of this patients 87.8% were ≤T2a, 12.2% T2b-c. Mean PSA: 6.73ng/ml (range 4.06–16.7). 87.8% were Gleason≤6 and 7 (3 + 4)
12.2%. Median Prostate volumen was 33 cm3, only one patient had volume 53.8 cm3. System Quick-Link was used with real-time
planiﬁcation, inserting a median of 16 needles and 60 seeds (range 38–82) to cover PTV with 145Gy isodose in radical intent
(92.6%) and 108Gy in combined with EBRT (7.4%) We used Constraints recommended by ESTRO: Uretra D10≤150Gy and during
the progress of learning curve was amended to Uretra D1≤150Gy. Rectum V100≤5%.
Results. Mean V100 in Rectum was 2.9% (between 0.1 and 9.68), 85% of patients with V100≤5% (35/41 patients). Mean D1 in
Uretra was 138Gy (between 121 and 196.8). 88% of patients with D1≤150Gy (36/41 patients). All patients had UrethraD10≤150Gy
following ESTRO recommendations. No patient had complications during the procedure and they all were discharged in the ﬁrst
24h. 1 patient (2.4%) required catheterization for acute urinary retention and there were no cases of acute rectal toxicity.
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Conclusion. The mean V100 in the rectum and D1 in urethra in prostate brachytherapy improve with real-time planiﬁcation and
Quick-Link construction seed system. This method allows getting greater limitations and achievement of constraints recom-
mendations of ESTRO.
http://dx.doi.org/10.1016/j.rpor.2013.03.040
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Introduction. MR-based Image Guided Adaptive BT (IGABT) for cervical cancer patients has been introduced at our institution
since November 2012. The present work compares preliminary IGABT dosimetric results to standard point A plans.
Material and methods. 36 MR based IGABT applications of 7Gy each were revised. FIGO stage distribution was: IB = 8, IIB = 24, IIIB = 4.
GTV, HRCTV, IRCTV and OARs were contoured according GEC-ESTRO guidelines. Median volume for HRCTV was 15.7 cm3 (IB),
28.3 cm3 (IIB) and 75 cm3 (IIIB). All patients received treatment based IGABT plan optimized upon the 4.6Gy; ≤4.6Gy; Sigmoid
D2cc≤7.7Gy; Rectum D2cc≥ following constraints: HRCTVD90 6.4Gy per fraction. A standard point A plan was generated for
each≤Bladder D2cc case and dosimetric data compared.
Results. For the 32 FIGO I-IIB cases median HRCTV D90 was 9.6 vs. 7.7Gy with standard or IGABT plan respectively. Overall 71.4%
of cases had at least 1 violation of the OARs constraints when a standard plan was applied. In details in 16.7% of cases the
standard planiﬁcation violated Rectum constraint, in 52.8% of cases there was a violation of Sigmoid, and in 22.2% of Bladder
constraint. OAR constraints were always met with IGABT. For the 4 IIIB cases (pelvic wall invasion) median HRCTVD90 was 5.6 vs.
7.3Gy 20%≈with standard or IGABT plan respectively. The HRCTV dose escalation (increment with IGABT) was reached without
increasing dose to OAR or even decreasing the median D2cc dose received with standard planiﬁcation: Rectum 4.6 vs. 4.6Gy
(Standard vs. IGABT), Sigmoid 3.7 vs. 3.2Gy and Bladder 5.6 vs. 5.5Gy (Standard vs. IGABT).
Conclusion. Given the preliminary dosimetric data we expect that introduction of IGABT in our routine will reduce treatment
morbidity for patients with small cervical tumors where a higher cure rate and overall survival is expected and potentially a
signiﬁcant increase of local control in IIIB/IVA tumors where a safe dose escalation is provided.
http://dx.doi.org/10.1016/j.rpor.2013.03.041
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Introduction. The beneﬁts of IMRT in external radiotherapy and MR imaging for Brachytherapy planning are established providing
accurate veriﬁcation of the applicator position, identiﬁcation of the residual tumor and detection of procedure-related compli-
cations. On the other hand IMRT planning with MRI and PET-TAC provides, an opportunity for conformal dose distribution to
tumor volume and organs at risk, as well the possibility for dose escalation with SIB (simultaneous integrated Boost) in a short
time, leading to improve local control and reduced toxicity.
Objective. To evaluate the dosimetry of MRI based brachytherapy combined with IMRT with PET-CT in a group of patients with
locally advanced cervix cancer.
Methods. In the period 2007–2012, 19 patients with cervix cancer stages IIB-IVA were treated with deﬁnitive radiochemotherapy
and brachytherapy. We used PET-CT and MRI for IMRT and MRI for brachytherapy to delineate the GTV, CTV, PTV and OAR. The
MRI is routinely performed in our center to stage the tumor and use it for planning the IMRT, we perform other MRI preimplant
and another one with the intracavitary device in place. Dose-volume histograms were calculate to evaluate IMRT, and to evaluate
the Brachytherapy we have reported D1cc, D2cc and D5cc to the rectum, bladder and sigmoid, and to the CTV we evaluated V90,
V100, D90, D95 and D100.
Result. Dosimetric study has demonstrated that IMRT achieves comparable PTV coverage compared with other approaches and
provides the opportunity to spare critical normal tissue and reduce the mean doses in bladder and rectum. This is very important
to offer the possibility for the better HDR brachytherapy with a very signiﬁcant improvement in dose optimisation and dosimetry.
Conclusion. MRI plays a comprehensive role in primary tumor staging. It monitors response to treatment and helps in the planning
of IMRT and Brachytherapy.
http://dx.doi.org/10.1016/j.rpor.2013.03.042
